- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03544476
Mobile Health Intervention for Active Tuberculosis
Interactive Mobile Health Intervention to Support Patients With Active Tuberculosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Tuberculosis (TB) remains a top ten leading cause of death globally despite it being a largely curable disease. New effective treatment supervision strategies are needed particularly in low-resource high TB burden settings and a potential solution is in the hands of nearly every patient - a mobile phone. Modern modular design mobile phone software applications ("apps") hold great promise to address this unmet need.
Current technologies allows for rapid design modification based on end user needs, implementation of native operating system (e.g., Android) versions for users with inconsistent internet access, and the integration of the patients' experiences with electronic health records using industry standards. Apps can perform multiple functions (e.g., automated reminders, symptom tracking, secure messaging, multi-media education). To date, few TB related apps have focused on patients as users, and none support patient engagement in self-management of their care or direct adherence monitoring. The research objectives are to understand end user needs and other stakeholder needs to build, refine, and pilot test an app to support patients self-administering treatment for active TB.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Province Of Buenos Aires
-
Vicente López, Province Of Buenos Aires, Argentina, 1602
- Hospital Dr. Antonio A. Cetrángolo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is starting TB treatment for the first time
- Subject has no known TB drug resistance
- Subject is HIV negative (self-reported or documented)
- Subject owns or has regular access to a mobile phone that can access the Internet and is able to operate the mobile phone to communicate or have someone able to assist.
Exclusion Criteria:
- Severely ill (i.e., requiring hospitalization)
- Reside in the same household with another study participant
- History of known drug resistance and HIV co-infection because their care is managed separately and the treatment regimens and duration differ.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mobile phone TB treatment support app
Daily use of the mobile phone TB treatment support app plus usual care.
Participants will be asked to self-report daily TB medication administration, side-effects when applicable, and complete the direct adherence paper-based test randomly on 3-4 days of the week during the intensive treatment phase (first two months) and then 1-2 times per week during the maintenance phase (about month 3-6).
|
The behavioral intervention is delivered through a mobile phone TB support app.
The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report.
The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app.
The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician.
In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
|
Active Comparator: Usual care
Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician.
In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
|
Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician.
In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability (perceived usefulness and ease of use)
Time Frame: 6 months
|
The Mobile Application Rating Scale (MARS) is a 19-item.
The scale includes three sections and a modifiable app-specific section: classification, quality and satisfaction classification section provides descriptive information about the apps.
The objective app quality section includes 19-items divided into four scales: engagement, functionality, aesthetics and information quality.
The subjective quality section contains 4 items evaluating the user's overall satisfaction.
MARS items are scored using a 5-point Likert scale.
The final MARS scores include four subscale scores, a total mean score, subjective quality score and an app-specific subscale that assesses perceived impact on the user's knowledge, attitudes, and intentions to change as well as likelihood of changing targeted behaviors.
|
6 months
|
Feasibility of implementation
Time Frame: 6 months
|
Semi-structured interview with participants to understand challenges, recommendations for improvement.
Observations
|
6 months
|
Initial efficacy - Treatment outcome
Time Frame: 6 months
|
Treatment outcomes will be measured using standard definitions set by the World Health Organization (WHO) Standards of TB treatment.
Treatment success based on WHO definitions: completed (without bacteriological confirmation) or cured (negative sputum smear at 6 months and at least once prior to 6 months)).
Other treatment outcomes include: failed (sputum smear positive at 5 months or later), died, defaulted (treatment interruption for ≥ 2 months), lost to follow-up (diagnosed, treatment outcome not documented), or transferred out (transferred to another reporting unit and treatment outcome is unknown).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global Health Patient-Reported Outcomes Measurement Information System (PROMIS) short form
Time Frame: day 1 and 6 months
|
The Global Health short form (SF) is a recommended outcome measure for self-management, includes 10 items
|
day 1 and 6 months
|
Tuberculosis Knowledge Assessment Questionnaire
Time Frame: day 1 and 6 months
|
Items include questions focused on exploring knowledge about: causes and symptoms of TB (5 items), TB transmission (4 items), TB treatment (2 items), and TB prevention (5 items).
The questions are structured to answer (yes, no, I don't know).
|
day 1 and 6 months
|
Engagement
Time Frame: 6 months
|
Level of engagement using the app will be measured by percentage of notification without a reminder, number of questions, number of reported side effects.
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sarah Iribarren, PhD, RN, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00002080
- K23NR017210 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Mobile phone TB treatment support app plus usual care
-
University of MichiganWashington University School of Medicine; National Institute of Nursing Research...Completed
-
University of TorontoCompletedPostpartum DepressionCanada
-
Chang Gung Memorial HospitalUnknown
-
University of California, Los AngelesCalifornia HIV/AIDS Research Program; Friends Research Institute, Inc.; Charles... and other collaboratorsCompletedHIV Infections | Hepatitis C | Substance Use Disorders | Sexually Transmitted Diseases, BacterialUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)Completed
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Consorci Sanitari del MaresmeNot yet recruitingAttention Deficit Disorder With Hyperactivity
-
Kaiser PermanenteWithdrawnDepression | Adolescent Behavior | Social MediaUnited States
-
Qazvin University Of Medical SciencesUnknownCardiovascular Diseases | HypertensionIran, Islamic Republic of
-
Oregon Center for Applied Science, Inc.National Heart, Lung, and Blood Institute (NHLBI)CompletedBlood Pressure | WeightUnited States